CHRISTOPHER KROEGER, M.D., M.B.A.
Chief Executive Officer
Dr. Kroeger joined OvaScience as Chief Executive Officer in September 2017. He brings more than 20 years of experience leading, building and advising development-stage therapeutic and medical device companies, as well as the expertise of a physician and scientist. Most recently, he served as CEO of Cardioxyl Pharmaceuticals, leading teams that produced three investigational new drug candidates and successfully executed six Phase 1 and Phase 2 clinical studies, culminating in the sale of the company to Bristol Myers Squibb for $2.1 billion in total consideration. Prior to his position at Cardioxyl, he led investing efforts as a Partner at The Aurora Funds, a venture capital firm focused on early-stage biotechnology and medical device companies. Earlier in his career, he held positions at Genzyme and Decision Resources.
Dr. Kroeger earned his B.A. from Harvard University, his M.D. from Stanford University School of Medicine and did his Residency in General Surgery at the Brigham and Women’s Hospital, an affiliate of Harvard Medical School. He also holds his M.B.A. from Harvard Business School. Dr. Kroeger currently serves on the Board of Directors of CardioFocus, Inc. and Cantex Pharmaceuticals, Inc.
JAMES LILLIE, Ph.D.
Chief Scientific Officer
Dr. Lillie joined OvaScience in January 2018. He brings extensive cellular biology and biochemistry experience to OvaScience, and leads the Company’s preclinical research and development efforts, including the continued advancement of OvaPrime and OvaTure. Dr. Lillie has more than 25 years of experience driving preclinical research and development across diverse therapeutic areas. He joins OvaScience from Sanofi Genzyme where he was Vice President of In Vitro Biology. In this role, Dr. Lillie was responsible for developing a scientific strategy for creating a sustainable, high value portfolio in rare diseases. He established a strong pipeline of small molecule drugs and supported the U.S. Food and Drug Administration’s approval of Eliglustat and acceptance of two investigational new drug applications. Previously, he was Senior Director, In Vitro Biology at Sanofi Genzyme and, before that, he held roles of increasing responsibility at Millennium Pharmaceuticals, Inc. Earlier, he worked as Senior Director, Biology at Scriptgen Pharmaceuticals, and as co-founder at AMIRA, which was later sold to Repligen Corporation.
Dr. Lillie holds a Ph.D. in Biochemistry and Molecular Biology from Harvard University and B.A. in German Literature from Wesleyan University.
JONATHAN GILLIS, C.P.A.
Mr. Gillis has been with OvaScience for nearly five years. In his role at OvaScience, he oversees the finance department and manages all SEC filings, budgets and works directly with the Audit and Compensation Committees. He is active in investor relations and leads the human resources, information technology and legal functions. He has more than 15 years of combined public accounting and overall financial industry experience. Previously, as Senior Director of Global Finance and Operations at OvaScience, Mr. Gillis was based in the United Kingdom and established the international headquarters for the Company. He was also instrumental in multiple OvaScience public offerings. Prior to joining OvaScience, Mr. Gillis was a Senior Manager of External Reporting and Compliance at GFI Software where he prepared the company for its initial public offering and managed SEC compliance. Earlier in his career, Mr. Gillis was a Manager at PricewaterhouseCoopers, LLP, where he was responsible for all stages of integrated and non-integrated audit engagements with clients ranging from million-dollar private companies to multi-billion-dollar public companies.
Mr. Gillis holds a B.S. and a M.S. in Accounting from Babson College.
LOUIS S. VILLALBA
SVP, Corporate Development
Mr. Villalba has been with OvaScience since November 2015 and most recently served as General Manager, North America. He brings more than 25 years of industry experience in developing and commercializing innovative therapies. Prior to OvaScience, Mr. Villalba was Chief Business Officer at Evofem, a startup company that specializes in women’s health, where he led portfolio development and managed strategic partnerships. Prior to Evofem, Mr. Villalba served as Global Vice President of Sales at Auxogyn, a TPG Texas Pacific Group and Kliener Perkins company that specializes in in vitro fertilization products, where he secured a key strategic partnership with Merck Serono for European commercialization. Earlier in his career he worked at Conceptus and served as the General Manager of Europe. He was part of the team that completed the $1.1 billion sale of the company to Bayer AG.
Mr. Villalba earned a B.A. in Business Management at Menlo College.